Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Lublin – page 59

814 clinical trials in Lublin, Poland across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Lublin at a glance
814
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

814 trials in Lublin

Open in trial search

Advanced systemic mastocytosis

Not recruiting

Study on the Safety and Effectiveness of Bezuclastinib for Patients with Advanced Systemic Mastocytosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:3,4-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-Yl)-1H-Pyrazole-5-Carboxamide
  • Sponsor:Cogent Biosciences Inc.

Hand dermatitis

Not recruiting

Study on Abrocitinib for Patients with Moderate to Severe Chronic Hand Eczema Unresponsive to Corticosteroids

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abrocitinib
  • Sponsor:Innovaderm Research Inc.

Non-small cell lung cancer

Not recruiting

Study of Immunotherapy Combinations with GSK4428859, Dostarlimab, and GSK6097608 for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Colitis ulcerative

Not recruiting

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Study on OM-85 for Preventing Respiratory Infections in Children with Wheezing Illness (Ages 6 Months to 5 Years)

Not recruiting
Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Sponsor:OM Pharma SA

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study Comparing Crovalimab and Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently on Complement Inhibitors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Chronic lymphocytic leukaemia

Not recruiting

Study of pirtobrutinib, venetoclax and rituximab combination compared to venetoclax and rituximab in previously treated Chronic Lymphocytic Leukemia patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

Not recruiting
Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Lublin

What the registry says about research in the country

01 Respiratory Health Research

Innovative clinical trials focusing on respiratory viral infections and preventive vaccines. Studies include investigations of RSV, human metapneumovirus, and influenza vaccines for older adults, alongside research on pneumococcal infections in children.

  • RSV and hMPV Prevention
  • Influenza Vaccine Development
  • COPD Treatment Studies

Current research emphasizes vaccine efficacy and immune response in vulnerable populations.

02 Dermatological Studies

Comprehensive research into dermatological conditions, with particular focus on psoriasis treatments. Multiple trials evaluating new therapeutic approaches for plaque psoriasis and genital psoriasis.

  • Plaque Psoriasis Treatments
  • Genital Psoriasis Therapy
  • Lichen Sclerosus Studies

Emphasis on developing targeted therapies for moderate to severe cases.

03 Chronic Disease Management

Advanced research into various chronic conditions, including Parkinson's disease, inflammatory bowel diseases, and cardiovascular conditions. Studies focus on innovative treatments and disease management approaches.

  • Heart Failure Prevention
  • Autoimmune Conditions
  • Neurological Disorders

Trials aim to improve patient outcomes through novel therapeutic interventions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.